# Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

> **NCT06701903** · PHASE2 · RECRUITING · sponsor: **Intra-Cellular Therapies, Inc.** · enrollment: 570 (estimated)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** ITI-1284 10 mg
- **DRUG:** ITI-1284 20 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06701903
- **Lead sponsor:** Intra-Cellular Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 570 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06701903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06701903, "Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06701903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*